Compare MIGI & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIGI | PSTV |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 37.2M |
| IPO Year | 2013 | 2016 |
| Metric | MIGI | PSTV |
|---|---|---|
| Price | $4.71 | $5.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | ★ 167.5K | 130.2K |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,754,085.00 | $5,213,000.00 |
| Revenue This Year | N/A | $13.20 |
| Revenue Next Year | N/A | $261.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $0.13 |
| 52 Week High | $15.80 | $8.00 |
| Indicator | MIGI | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 42.17 |
| Support Level | $3.95 | $0.37 |
| Resistance Level | $5.20 | $6.65 |
| Average True Range (ATR) | 1.19 | 0.47 |
| MACD | -0.15 | -0.14 |
| Stochastic Oscillator | 23.12 | 3.45 |
Mawson Infrastructure Group Inc is focused on digital infrastructure platforms. It designs, builds and operates next-generation digital infrastructure platforms for enterprise customers and for its own purposes. The company provides services spanning AI, HPC, digital assets including Bitcoin mining, and other intensive compute applications. The company delivers both self-mining operations and colocation services to enterprise customers with a vertically integrated infrastructure model built for scalability and efficiency. The company also has an energy management business, which utilizes software and analysis, to generate revenue by participating in energy management programs. It operates as one energy management and digital asset mining segment.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).